Jacobson Pharma's IFRS net income for fiscal 2022 was HK$187.705 million, up 0.7% from HK$186.308 million in the previous year. Revenue increased 10.3% to HK$1.595 billion versus HK$1.446 billion a year earlier.
Jacobson Pharma's IFRS net income for fiscal 2022 was HK$187.705 million, up 0.7% from HK$186.308 million in the previous year. Revenue increased 10.3% to HK$1.595 billion versus HK$1.446 billion a year earlier. 
www1.hkexnews.hk
English (US) 